Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

NCT ID: NCT05519917

Last Updated: 2022-09-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-01
• Study Completion Date: 2025-12-30

Brief Summary

This is a single arm, open label, single center, and prospective, interventional study to explore clinical efficacy of afatinib in patients with chordoma of skull base. Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle. The primary objective is to assess the efficacy of afatinib in chordoma of skull base by objective response rate (ORR). The Secondary objectives is to assess progression free survival (PFS), overall survival (OS), tumor response duration and tumor shrinkage degree in patients with chordoma of skull base after using afatinib; to evaluate the safety and tolerability of afatinib in patients with chordoma of skull base.

Conditions

Chordoma of Clivus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Afatinib

Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle.

Group Type: EXPERIMENTAL

Afatinib

Intervention Type: DRUG

Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.

Interventions

Afatinib

Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients of 18 years and above;
• Patients with pathologically proven EGFR and/or HER2 expressing relapsed or residual chordoma of skull base, inappropriate or unwilling to receive surgery or radiotherapy;
• Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 75 x 109/L);
• An adequate renal function with GFR ≥ 45 ml/min calculated by Cockroft-Gault formula;
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 times ULN;
• Ability to swallow medication;
• Able to understand and provide written informed consent prior to any study procedures.

Exclusion Criteria

• Life expectancy of less than 3 months;
• Known hypersensitivity to afatinib;
• Major surgery less than 4 weeks prior to start of the study;
• Patients who once participated in other clinical trials within 14 days before the initiation of the study;
• Systemic anti-cancer therapy within 28 days prior to start of the study;
• No tumor progression after radiation therapy prior to start of the study;
• History or presence of serious cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥ 3, unstable angina or poorly controlled arrhythmia, and myocardial infarction within 6 months prior to inclusion;
• Known pre-existing interstitial lung disease;
• No response after 2-week active treatment for known CTCAE Grade 3 or Grade 2 rash/acne;
• Any history or presence of poorly controlled gastrointestinal disorders that may worsen after administration and could affect the absorption of the study drug (e.g. diarrhea, Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption);
• Active hepatitis B infection (HepB sAg and/ or Hep B DNA positive), active hepatitis C infection (Hep C RNA positive), active tuberculosis and/or known HIV carrier;
• Using other drugs that may influence afatinib and cannot be discontinued during the study, including but not limited to:
• Potent P-gp inhibitors: including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir and amiodarone);
• Potent P-gp inducers: including but not limited to rifampin, carbamazepine, phenytoin, phenobarbital or St. John's wort).
• Pregnant or lactating women;
• Other invasive malignancies diagnosed within the last 5 years (except non-melanoma skin cancer and localized cured prostate and cervical cancer);
• Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: collaborator

Huashan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Zhaoyun Zhang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Huashan Hospital

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Qilin Zhang, MD

Role: CONTACT

Phone: 86-21-52889999

Email: zhangqlhuashan@163.com

Other Identifiers

KY2019-610

Identifier Type: -

Identifier Source: org_study_id